BACKGROUND: Iron deficiency is common among female injection drug users, but it is unclear whether iron supplementation can reduce anemia and improve iron status without increasing plasma hepatitis C virus (HCV) or HIV RNA levels. METHODS: We conducted a phase 3, double-blind, randomized, controlled clinical trial of daily micronutrients with 18 mg of iron (iron group) versus micronutrients without iron (control group) for 12 months among hepatitis C-positive female injection drug users in Baltimore, Maryland. The main outcome measures were hemoglobin, markers of iron status, plasma HCV RNA, plasma HIV RNA, and liver enzymes at 6 and 12 months of follow-up. RESULTS:Four hundred fifty-eight women (320 HIV-negative and 138 HIV-positive) enrolled in the trial. There were no significant differences in the proportion of women with anemia, ferritin<30 ng/mL, log10 plasma HCV RNA, or log10 plasma HIV RNA between treatment groups at enrollment. The proportion with anemia in the iron and control groups, respectively, was 20.7% versus 31.3% (P=0.026) at 6 months and 26.2% versus 30.4% (P=0.5) at 12 months; with ferritin<30 ng/mL, the proportion was 29.2% versus 55.5% (P<0.0001) at 6 months and 26.2% versus 46.9% (P=0.0018) at 12 months. In the iron and control groups, respectively, mean log10 plasma HCV RNA (IU/mL) was 5.2 versus 5.2 (P=0.86) at 6 months and 5.4 versus 5.3 (P=0.6) at 12 months. Among HIV-positive subjects, mean log10 plasma RNA (copies/mL) in the iron and placebo groups, respectively, was 3.8 versus 3.7 (P=0.75) at 6 months and 3.7 versus 4.1 (P=0.19) at 12 months. There were no significant differences in liver enzyme levels between the treatment groups at enrollment, 6 months, and 12 months. CONCLUSIONS: A daily micronutrient supplement with iron can reduce anemia and improve iron status in female injection drug users without increasing plasma HCV or HIV RNA levels or altering liver enzymes.
RCT Entities:
BACKGROUND:Iron deficiency is common among female injection drug users, but it is unclear whether iron supplementation can reduce anemia and improve iron status without increasing plasma hepatitis C virus (HCV) or HIV RNA levels. METHODS: We conducted a phase 3, double-blind, randomized, controlled clinical trial of daily micronutrients with 18 mg of iron (iron group) versus micronutrients without iron (control group) for 12 months among hepatitis C-positive female injection drug users in Baltimore, Maryland. The main outcome measures were hemoglobin, markers of iron status, plasma HCV RNA, plasma HIV RNA, and liver enzymes at 6 and 12 months of follow-up. RESULTS: Four hundred fifty-eight women (320 HIV-negative and 138 HIV-positive) enrolled in the trial. There were no significant differences in the proportion of women with anemia, ferritin<30 ng/mL, log10 plasma HCV RNA, or log10 plasma HIV RNA between treatment groups at enrollment. The proportion with anemia in the iron and control groups, respectively, was 20.7% versus 31.3% (P=0.026) at 6 months and 26.2% versus 30.4% (P=0.5) at 12 months; with ferritin<30 ng/mL, the proportion was 29.2% versus 55.5% (P<0.0001) at 6 months and 26.2% versus 46.9% (P=0.0018) at 12 months. In the iron and control groups, respectively, mean log10 plasma HCV RNA (IU/mL) was 5.2 versus 5.2 (P=0.86) at 6 months and 5.4 versus 5.3 (P=0.6) at 12 months. Among HIV-positive subjects, mean log10 plasma RNA (copies/mL) in the iron and placebo groups, respectively, was 3.8 versus 3.7 (P=0.75) at 6 months and 3.7 versus 4.1 (P=0.19) at 12 months. There were no significant differences in liver enzyme levels between the treatment groups at enrollment, 6 months, and 12 months. CONCLUSIONS: A daily micronutrient supplement with iron can reduce anemia and improve iron status in female injection drug users without increasing plasma HCV or HIV RNA levels or altering liver enzymes.
Authors: Valerie L Flax; Linda S Adair; Lindsay H Allen; Setarah Shahab-Ferdows; Daniela Hampel; Charles S Chasela; Gerald Tegha; Eric J Daza; Amanda Corbett; Nicole L Davis; Deborah Kamwendo; Athena P Kourtis; Charles M van der Horst; Denise J Jamieson; Margaret E Bentley Journal: J Nutr Date: 2015-07-08 Impact factor: 4.798
Authors: Christopher T Andersen; Christopher P Duggan; Karim Manji; George R Seage; Donna Spiegelman; Nandita Perumal; Nzovu Ulenga; Wafaie W Fawzi Journal: Int J Epidemiol Date: 2022-10-13 Impact factor: 9.685
Authors: Rudi Wisaksana; Rachmat Sumantri; Agnes R Indrati; Aleta Zwitser; Hadi Jusuf; Quirijn de Mast; Reinout van Crevel; Andre van der Ven Journal: BMC Infect Dis Date: 2011-08-09 Impact factor: 3.090
Authors: George M Carter; Debbie Indyk; Matthew Johnson; Michael Andreae; Kathryn Suslov; Sudharani Busani; Aryan Esmaeili; Henry S Sacks Journal: PLoS One Date: 2015-04-01 Impact factor: 3.240
Authors: Juliana Lauar Gonçalves; Maria Clara Amorim Silva; Eric Henrique Roma; Beatriz Grinsztejn; Alberto Dos Santos de Lemos; Nathalia Gorni; Adele Moura Cruz; Cristiane Fonseca de Almeida; Marcel de Souza Borges Quintana; Maria da Gloria Bonecini-Almeida; Patrícia Dias de Brito Journal: Mem Inst Oswaldo Cruz Date: 2020-01-31 Impact factor: 2.743
Authors: Louise Balfour; Johanna N Spaans; Dean Fergusson; Harold Huff; Edward J Mills; Charles J la Porte; Sharon Walmsley; Neera Singhal; Ron Rosenes; Nancy Tremblay; M John Gill; Hugues Loemba; Brian Conway; Anita Rachlis; Edward Ralph; Mona Loutfy; Ranjeeta Mallick; Rika Moorhouse; D William Cameron Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240
Authors: Minke H W Huibers; Imelda Bates; Steve McKew; Theresa J Allain; Sarah E Coupland; Chimota Phiri; Kamija S Phiri; Michael Boele van Hensbroek; Job C Calis Journal: PLoS One Date: 2020-02-25 Impact factor: 3.240